🟢 CHM.AX is trading 5.3% up today as investors reassess its strategic review

CHM.AX is trading 5.3% up at $0.06 as investors reassess the impact of the company's strategic review and capital management plans.

• The stock is rebounding from a sharp 12.31% decline on July 1, 2026, following a selloff triggered by the announcement of a strategic review.
• Chimeric Therapeutics recently appointed Hawkesbury Partners as an independent financial adviser to lead the review aimed at unlocking shareholder value.